LDBB.F H. LUNDBECK A/S SER.A DK1
- Market cap
- EUR 7.62B
- P/E
- 14.0x
- P/B
- 2.02x
- ROE
- 19.2%
- Dividend yield
- 2.00%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LDBB.F undervalued?
Graham numberLDBB.F trades 12.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
H. LUNDBECK A/S SER.A DK1 fundamental analysis
No fundamental analysis for H. LUNDBECK A/S SER.A DK1 yet.
H. LUNDBECK A/S SER.A DK1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About H. LUNDBECK A/S SER.A DK1
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Ci…
Full company profileH. LUNDBECK A/S SER.A DK1 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
H. LUNDBECK A/S SER.A DK1 annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 18.2B | 19.9B | 22.0B | 24.6B | 26.9B |
| Gross Profit | 14.3B | 15.4B | 17.8B | 20.4B | 22.0B |
| Operating Income | 2.85B | 3.20B | 3.27B | 5.28B | 7.21B |
| EBITDA | 4.39B | 5.06B | 5.71B | 6.87B | 7.21B |
| Net Income | 1.92B | 2.29B | 3.14B | 3.19B | 5.43B |
| EPS | 1.93 | 2.31 | 3.17 | 3.22 | 5.47 |
| Balance Sheet | |||||
| Total Assets | 37.5B | 37.4B | 57.7B | 52.1B | 53.8B |
| Total Liabilities | 16.7B | 15.4B | 32.7B | 27.2B | 25.6B |
| Shareholders' Equity | 20.8B | 22.0B | 25.0B | 24.9B | 28.3B |
| Cash & Short-term Investments | 3.42B | 5.01B | 4.66B | 3.43B | 3.67B |
| Cash Flow | |||||
| Operating Cash Flow | 3.52B | 4.08B | 3.33B | 5.48B | 6.68B |
| Capital Expenditure | 820M | 501M | 565M | 618M | 604M |
| Free Cash Flow | 2.70B | 3.58B | 2.76B | 4.86B | 6.08B |
| Ratios | |||||
| ROE | 9.2% | 10.4% | 12.6% | 12.8% | 19.2% |
| ROA | 5.1% | 6.1% | 5.5% | 6.1% | 10.1% |
| Net Profit Margin | 10.5% | 11.5% | 14.3% | 13.0% | 20.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
H. LUNDBECK A/S SER.A DK1 dividends
- Dividend yield
- 2.00%
- Forward dividend
- 0.15 EUR
- Payout ratio
- 29.5%
- Ex-dividend date
- Mar 19, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | DKK 943M | 0.95 | 29.5% |
| 2024 | DKK 694M | 0.70 | 22.1% |
| 2023 | DKK 576M | 0.58 | 25.2% |
| 2022 | DKK 397M | 0.40 | 20.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns H. LUNDBECK A/S SER.A DK1
- Insiders 0.08%
- Institutions 82.19%
- Public & others 17.73%
- Shares outstanding 199M
- Free float 304M
H. LUNDBECK A/S SER.A DK1 company profile
- Company name
- H. LUNDBECK A/S SER.A DK1
- Ticker
- LDBB.F
- ISIN
- DK0061804697
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,000
- Fiscal year end
- December
- Address
- Ottiliavej 9, Valby, Denmark, 2500
- Phone
- 45 36 30 13 11
- Website
- lundbeck.com
About H. LUNDBECK A/S SER.A DK1
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
H. LUNDBECK A/S SER.A DK1 management
10- Mr. Charl van ZylPresident & CEO · born 1967
- Mr. Joerg HornsteinCFO & Executive VP of Corporate Functions · born 1977
- Dr. Per Johan Luthman Ph.D.Advisor · born 1959
- Dr. Tarek Samad Ph.D.Executive VP and Head of Research & Development
- Jens HoyerVice President & Head of Investor Relations
- Ms. Dianne HoltoExecutive Vice President of People, Culture & Sustainability · born 1973
- Mr. Thomas E. GibbsExecutive VP & Head of Lundbeck in United States · born 1971
- Prof. Johannes Rolf Streffer M.D.Senior VP & Head of Global Clinical Development · born 1969
- Ms. Michala Fischer-HansenExecutive VP and Head of Europe & International Markets and Operations · born 1974
- Ms. Tine Ostergaard HansenSenior Vice President of Corporate Affairs · born 1975